Holcombe Grier, MD
| Department | Hematology/Oncology |
 |
| Hospital Title: | Associate in Medicine | |
| Academic Title: | Professor of Pediatrics | |
| Phone: | 617-632-3971 | |
| Fax: | 617-632-5710 | |
| Email: | Holcombe Grier | |
| Location: |
Dana-Farber Cancer Institute 44 Binney Street Boston, MA 0211 |
Research Overview
Dr. Grier's major research focus has been the clinical management, treatment, and biology of solid tumors in children, particularly Ewing's sarcoma. His major research has been at the national level through clinical trials undertaken by the Children's Oncology Group, a consortium of cancer treatment centers across the United States, Canada, and other countries. Dr. Grier is on the steering committee of the Bone Tumor Committee.
In addition to his national research positions, Dr. Grier is also part of the Pediatric Solid Tumor group at DFCI and Children's Hospital. Dr. Grier and colleagues help organize laboratory and clinical cross talk and development of lab bench to bedside clinical research.
Dr. Grier is also involved in cancer survivor studies that focus on the late effects of chemotherapy, studies which are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at DFCI. In addition, he participates in a study of the best application of palliative care through work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.
About Holcombe Grier
Holcombe Grier received his MD from the University of Pennsylvania. He trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina. He was a fellow in pediatric hematology/oncology at Children’s Hospital and the Dana-Farber Cancer Institute.
He is a past president of the American Society of Pediatric Hematology/Oncology. He received the Charles A. Janeway Award for Excellence in Clinical Teaching of Children's Hospital House Staff in 1992, a Harvard Medical School Faculty Prize for Excellence in Teaching [Years III and IV] in 2008 and a Harvard Medical School Community Service award in 2009.
Key Publications
- Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJH, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Myers PA, Donaldson SS, Moore S, Rausen MD, Vietti TJ, Miser JS. Addition of ifosfamide and etoposide to standard chemotherapy in Ewing sarcoma/primitive neuroectodermal tumor of bone: A Children's Cancer Group/Pediatric Oncology Group Study. N Engl J Med 348:694-701, 2003.Loh ML.
- Mack JW, Wolfe J, Cook EF, Grier HE, Cleary PD, Weeks JC: Parents' roles in decision making for children with cancer in the first year of cancer treatment. J Clin Oncol. 2011 May 20;29(15):2085-90. Granowetter L, Womer RB, Devidas M, Krailo MD, Wang C, Bernstein ML, Marina N, Leavey PJ, Gebhardt M, Healey JH, Shamberger RC, Goorin AM, Miser J, Meyer M, Arndt CAS, Sayler S, Marcus KJ, Perlman EJ, Dickman PS, Grier HE: Comparison of dose intensified versus standard chemotherapy for non-metastatic Ewing Sarcoma Family of Tumors (ESFT): A Children?s Oncology Group Study Report. J Clin Oncol 27:2536-2541, 2009. [Epub ahead of print April 6, 2009].
- Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, Seibel NL, Grier HE, Gorlick R, Marina N.: Outcome for adolescent and young adult patients with osteosarcoma: A report from the Children's Oncology Group. Cancer. 2012 Jan 17.
- Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz S, Krailo M, Devidas M, Barkauskas D, Siegal G, Ferguson W, Letson G, Marcus K, Goorin A, Beardsley P, Marina N: Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with HER2 overexpression: a report from the Children's Oncology Group. J Clin Oncol, in press
